Huapont Life Sciences

Huapont Life Sciences, established in 1992, is a prominent pharmaceutical manufacturing entity publicly traded on the Shenzhen Stock Exchange under the ticker SZSE: 002004.SZ. The company maintains a robust operational footprint within the healthcare sector, focusing on the research, development, and large-scale production of diverse therapeutic agents. Its portfolio spans critical medical categories, including dermatological drugs, respiratory system medications, anti-tumor treatments, antituberculosis drugs, and complex cardio-cerebrovascular medications. By integrating advanced chemical synthesis with rigorous quality control protocols, the firm serves both domestic and international healthcare markets.

The company operates a sophisticated manufacturing infrastructure, producing both finished dosage forms and high-purity active pharmaceutical ingredients. Huapont Life Sciences has secured significant regulatory validations for its API facilities, including certifications from the US-FDA, MEDSAFE, and COFEPRIS. These international approvals underscore the company's technical capability to meet stringent global manufacturing standards. By maintaining these regulatory benchmarks, the organization functions as a key exporter of pharmaceutical ingredients from China, supporting global supply chains with high-quality chemical and biological components essential for modern medical treatments.

With a workforce exceeding 10,000 employees, Huapont Life Sciences demonstrates significant operational scale and human capital investment. The company reported annual revenue of $1.6B, reflecting its substantial market presence and consistent output in the pharmaceutical industry. Meet Huapont Life Sciences's team to understand the organizational structure and leadership driving these technical operations. Headquartered in Chongqing, China, the firm continues to leverage its manufacturing expertise to expand its influence in the global life sciences sector.